



AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method for treating a CNS disorder associated with impaired prefrontal cortical function associated with activation of protein kinase C or impaired cognitive performance a working memory deficit in a subject comprising administering orally or systemically to said subject in need thereof an effective amount of a pharmaceutical composition comprising a compound or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof according to the structure:



(I)



(II)

wherein:

R¹ and R² are independently selected from H, C₁-C₃alkyl, F, Cl, Br, I, OH, O(C₁-C₆alkyl), O-C(=O)-(C₁-C₆)alkyl or C(=O)-O-(C₁-C₆)alkyl;

R³ is H or a C₁-C₆alkyl group;

R⁴, R⁵, R⁶, R⁷ and R⁸ are independently selected from H, C₁-C₆ alkyl, F, Cl, Br, I, OH, -(CH₂)_nO(C₁-C₆alkyl), -(CH₂)_nO-C(=O)-(C₁-C₆)alkyl or -(CH₂)_nC(=O)-O-(C₁-C₆)alkyl;

R⁹ and R¹⁰ are independently H, C₁-C₆alkyl or together form a -(CH₂)_m- group to produce a 5-7 membered ring;

n is from 0 to 53;

m is from 0 to 3;


and A⁻ is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2. (Original) A method of claim 1 wherein R¹ and R² are both OCH₃ groups, R³ is a CH₃ group, R⁴, R⁵, R⁶, R⁷ and R⁸ are each H, R⁹ and R¹⁰ are each H, CH₃ or together form a -CH₂- group to produce a five-membered ring; and A⁻ is Cl⁻, citrate or phosphate.

3. (Original) A method of claim 2, wherein R⁹ and R¹⁰ together form a -CH₂- group to produce a five-membered ring.

4. (Original) A method of claim 1, wherein the CNS disorder is a bipolar disorder.
5. (Withdrawn) A method of claim 1, wherein the CNS disorder is an anxiety disorder.
6. (Withdrawn) A method of claim 1, wherein the CNS disorder is stress-induced.
7. (Withdrawn) A method of claim 1, wherein the CNS disorder is attention deficit hyperactivity disorder (ADHD).
8. (Withdrawn) A method of claim 1, wherein the CNS disorder is schizophrenia.
9. (Withdrawn) A method of claim 1, wherein said subject is treated for impaired cognitive performance.
10. (Original) A method of claim 1, wherein the CNS disorder is associated with enhanced PKC activity.
11. (Withdrawn) A method of claim 9, wherein the impaired cognitive performance is induced or exacerbated by stress.
12. (Original) A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.
13. (Withdrawn) A method of claim 9, wherein the pharmaceutical composition is administered orally and the subject is a human.
14. (Original) A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.
- 15.-17. (Canceled)

18. (Currently Amended) A method of treatment comprising administering to a subject suffering from manic episodes associated with enhanced PKC activity a therapeutically effective amount of a composition according to claim 15 containing a compound of the formula of the structure:



(I)

wherein:

R^1 and R^2 are independently selected from H, C_1 - C_3 alkyl, F, Cl, Br, I, OH, $O(C_1$ - C_6 alkyl), $O-C(=O)-(C_1$ - C_6)alkyl or $C(=O)-O-(C_1$ - C_6)alkyl;

R^3 is H or a C_1 - C_6 alkyl group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently selected from H, C_1 - C_6 alkyl, F, Cl, Br, I, OH, $-(CH_2)_nO(C_1$ - C_3 alkyl), $-(CH_2)_nO-C(=O)-(C_1$ - C_3)alkyl or $-(CH_2)_nC(=O)-O-(C_1$ - C_3)alkyl;

R^9 and R^{10} are independently H, C_1 - C_6 alkyl or together form a $-(CH_2)_m-$ group to produce a 5-7 membered ring;

n is from 0 to 3;

m is from 0 to 3;

and A^- is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

19. (Original) A method of claim 18, wherein the manic episodes are also stress induced.

20. (Currently Amended) A method for treating manic episodes in a bipolar patient comprising ~~protecting a subject from developing a CNS disorder by administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 15~~ chelerythrine.

21. (Previously presented) A method of Claim 1, wherein the CNS disorder is bipolar disorder, schizophrenia, an anxiety disorder, impaired cognitive performance, or attention deficit hyperactivity disorder (ADHD).